Militia Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Militia Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.78M	Buy	+2,300	New	+$1.56M	0.67%	39

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Militia Capital Partners's REGN Position: Q4 2025 in Review

Militia Capital Partners opened a new position in Regeneron Pharmaceuticals (REGN) in Q4 2025: 2,300 shares worth $1.78M. The stake represents 0.67% of the portfolio and ranks #39 among its holdings.

1,386 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Militia Capital Partners held 2,300 shares of Regeneron Pharmaceuticals worth $1.78M as of Q4 2025.
Regeneron Pharmaceuticals was a new Militia Capital Partners position in Q4 2025.
Regeneron Pharmaceuticals made up 0.67% of Militia Capital Partners's portfolio in Q4 2025, its #39 holding.
1,386 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Militia Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.